Chemkart India Ltd

Auditors

• Statutory Auditor appointed: M/s Prem Chand Jain & Co. for 2026-27 to 2030-31, subject to shareholder approval.

Secretarial Auditor

• Secretarial Auditor appointed: M/s Nirmal Tiwari & Associates for 2026-27 to 2030-31, subject to shareholder approval.

AGM scheduling

• 7th AGM scheduled for 19 September 2026 at 12:00 PM IST via video conferencing.

Scrutinizer

• CS Nirmal Tiwari to scrutinize AGM voting.

Investment in subsidiary

• Target: Easy Raw Materials Private Limited, India-based trader of pharma products and nutritional supplements.
• Wholly owned subsidiary; Chemkart's shareholding remains 100% post allotment.
• Turnover NIL; loss after tax Rs 59.47 Lakhs; net worth Rs 578.60 Lakhs as on 31 Mar 2026.
• Paid-up capital post allotment Rs 8.51 Crore; authorized capital Rs 10 Crore; 85,10,000 shares issued.
• Cash consideration of Rs 1.00 Crore via rights issue; 10,00,000 equity shares at Rs 10 each.
• Percentage holding remains 100% pre- and post-allotment; related party transaction at arm’s length.
• Regulatory approvals: Not applicable.
• Completion timeline: Not Applicable.
• Strategic rationale: deploy IPO proceeds toward subsidiary's manufacturing unit.
• Background: Incorporated 2020; India; turnover nil in last three years.

Dematerialisation status

• No dematerialisation/rematerialisation requests were received during the reporting quarter.
• Regulation 74(5) not applicable as entire holding is in demat form.

Financial highlights

• Revenue from operations Apr-Jun FY27: INR 99.60 crore.
• First-quarter revenue ~50% of prior full-year with improved margins.

Subsidiary development

• Vinstar Biotech received trial orders for in-house value-added ingredients, marking proprietary formulations development.

Operational progress

• EZRM facility: plinth-level construction progressing; electricity sanction letter received; packaging machinery finalized.
• Delivery timing aligns with 30–35 days post-PO release for commissioning.

Strategic initiatives & outlook

• Investing in R&D to strengthen formulation and technical capabilities.
• Strategic expansion into functional ingredients including proteins and functional fibers.
• Shift to integrated solutions to strengthen customer relationships and margins.
• Outlook: continued nutraceutical demand growth; emphasis on quality, compliance and traceability.

Market activity

• Three industry exhibitions in H1 2026 across India and Europe; engaged customers.

Acquisition details

• Target Company: Chemkart India Limited.
• Disclosing Party: Jaini Shailesh Mehta (Promoter Group).
• Transaction Type: Acquisition of 1,200 equity shares.
• Pre-Transaction Holding: 4,207 shares, 0.03%.
• Transaction Details: 1,200 shares acquired (0.01%) via open market on BSE.
• Post-Transaction Holding: 5,407 shares, 0.04%.
• Date of Acquisition: 06 July 2026.
• Equity share capital before: INR 12,09,90,000 (1,20,99,000 shares).
• Equity share capital after: INR 12,09,90,000 (1,20,99,000 shares).
• Total diluted share capital: INR 12,09,90,000 (1,20,99,000 shares).

Promoter share acquisition

• Acquirer: Jaini Shailesh Mehta acquired 1,200 equity shares (0.01% of paid-up capital) on 06 July 2026.
• Mode: On-market; Transaction type: Purchase; Category: Promoter Group.
• Post-acquisition holding reported at 203,160 equity shares.
• Disclosure filed under SEBI PIT Regulations 7(2)(a)/(b).

Acquisition under Reg 29(2) details

• Target company: Chemkart India Limited.
• Disclosing party: Shailesh Vinodrai Mehta, promoter.
• Acquirer and PAC: Shailesh Vinodrai Mehta.
• Transaction type: Acquisition of 1,800 equity shares.
• Pre-transaction holding: 141,607 shares (1.17%).
• Acquisition mode: Open market on BSE.
• Date of transaction: 01 July 2026.
• Post-transaction holding: 143,407 shares (1.19%).
• Equity share capital before/after: 12,099,000 shares.
• Total diluted share capital: INR 12,09,90,000 comprising 1,20,99,000 equity shares.
• Acquirer belongs to promoter group: Yes.

Promoter acquisition and PIT disclosures

• Acquirer: Shailesh Vinodrai Mehta (DIN 10563871; PAN AABPM2251N) bought 1,800 equity shares on 01/07/2026.
• Acquisition represents 0.01% of Chemkart India's paid-up capital.
• PIT Form C disclosures filed with BSE.

Promoter share acquisition disclosed

• Company filed Form C disclosures under PIT 7(2)(b) regarding share acquisitions.
• Promoter Shailesh Mehta acquired 1,800 equity shares on-market on 01-Jul-2026.
• Post-acquisition holding amounts to 0.01% of paid-up capital.